Drug Profile

CJRB 201

Alternative Names: CJRB-201; CLP-105

Latest Information Update: 28 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator CJ Bioscience
Class Anti-inflammatories; Bacteria
Mechanism of Action Bacteria replacements; Gastrointestinal microbiome modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Preclinical Inflammatory bowel diseases

Most Recent Events

18 Feb 2025 Pharmacodynamics data from preclinical studies in Inflammatory bowel diseases released by CJ Bioscience
18 Feb 2025 CJ Biosciences plans a phase I trial for Inflammatory bowel disease in 2026
08 Aug 2023 CJRB 201 is available for licensing as of 08 Aug 2023. https://www.cjbioscience.com/pipeline

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com